2024-01-012024-12-312024-12-31false12944590WLNESS SCIENCE LTD2025-05-2372110falseiso4217:GBPxbrli:pure129445902024-01-01129445902024-12-31129445902024-01-012024-12-31129445902023-01-01129445902023-12-31129445902023-01-012023-12-3112944590bus:SmallEntities2024-01-012024-12-3112944590bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3112944590bus:AbridgedAccounts2024-01-012024-12-3112944590bus:PrivateLimitedCompanyLtd2024-01-012024-12-3112944590core:WithinOneYear2024-12-3112944590core:AfterOneYear2024-12-3112944590core:WithinOneYear2023-12-3112944590core:AfterOneYear2023-12-3112944590core:ShareCapital2024-12-3112944590core:SharePremium2024-12-3112944590core:RevaluationReserve2024-12-3112944590core:OtherReservesSubtotal2024-12-3112944590core:RetainedEarningsAccumulatedLosses2024-12-3112944590core:ShareCapital2023-12-3112944590core:SharePremium2023-12-3112944590core:RevaluationReserve2023-12-3112944590core:OtherReservesSubtotal2023-12-3112944590core:RetainedEarningsAccumulatedLosses2023-12-3112944590core:LandBuildings2024-12-3112944590core:PlantMachinery2024-12-3112944590core:Vehicles2024-12-3112944590core:FurnitureFittings2024-12-3112944590core:OfficeEquipment2024-12-3112944590core:NetGoodwill2024-12-3112944590core:IntangibleAssetsOtherThanGoodwill2024-12-3112944590core:ListedExchangeTraded2024-12-3112944590core:UnlistedNon-exchangeTraded2024-12-3112944590core:LandBuildings2023-12-3112944590core:PlantMachinery2023-12-3112944590core:Vehicles2023-12-3112944590core:FurnitureFittings2023-12-3112944590core:OfficeEquipment2023-12-3112944590core:NetGoodwill2023-12-3112944590core:IntangibleAssetsOtherThanGoodwill2023-12-3112944590core:ListedExchangeTraded2023-12-3112944590core:UnlistedNon-exchangeTraded2023-12-3112944590core:LandBuildings2024-01-012024-12-3112944590core:PlantMachinery2024-01-012024-12-3112944590core:Vehicles2024-01-012024-12-3112944590core:FurnitureFittings2024-01-012024-12-3112944590core:OfficeEquipment2024-01-012024-12-3112944590core:NetGoodwill2024-01-012024-12-3112944590core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3112944590core:ListedExchangeTraded2024-01-012024-12-3112944590core:UnlistedNon-exchangeTraded2024-01-012024-12-3112944590core:MoreThanFiveYears2024-01-012024-12-3112944590core:Non-currentFinancialInstruments2024-12-3112944590core:Non-currentFinancialInstruments2023-12-3112944590dpl:CostSales2024-01-012024-12-3112944590dpl:DistributionCosts2024-01-012024-12-3112944590core:LandBuildings2024-01-012024-12-3112944590core:PlantMachinery2024-01-012024-12-3112944590core:Vehicles2024-01-012024-12-3112944590core:FurnitureFittings2024-01-012024-12-3112944590core:OfficeEquipment2024-01-012024-12-3112944590dpl:AdministrativeExpenses2024-01-012024-12-3112944590core:NetGoodwill2024-01-012024-12-3112944590core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3112944590dpl:GroupUndertakings2024-01-012024-12-3112944590dpl:ParticipatingInterests2024-01-012024-12-3112944590dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3112944590core:ListedExchangeTraded2024-01-012024-12-3112944590dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3112944590core:UnlistedNon-exchangeTraded2024-01-012024-12-3112944590dpl:CostSales2023-01-012023-12-3112944590dpl:DistributionCosts2023-01-012023-12-3112944590core:LandBuildings2023-01-012023-12-3112944590core:PlantMachinery2023-01-012023-12-3112944590core:Vehicles2023-01-012023-12-3112944590core:FurnitureFittings2023-01-012023-12-3112944590core:OfficeEquipment2023-01-012023-12-3112944590dpl:AdministrativeExpenses2023-01-012023-12-3112944590core:NetGoodwill2023-01-012023-12-3112944590core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3112944590dpl:GroupUndertakings2023-01-012023-12-3112944590dpl:ParticipatingInterests2023-01-012023-12-3112944590dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3112944590core:ListedExchangeTraded2023-01-012023-12-3112944590dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3112944590core:UnlistedNon-exchangeTraded2023-01-012023-12-3112944590core:NetGoodwill2024-12-3112944590core:IntangibleAssetsOtherThanGoodwill2024-12-3112944590core:LandBuildings2024-12-3112944590core:PlantMachinery2024-12-3112944590core:Vehicles2024-12-3112944590core:FurnitureFittings2024-12-3112944590core:OfficeEquipment2024-12-3112944590core:AfterOneYear2024-12-3112944590core:WithinOneYear2024-12-3112944590core:ListedExchangeTraded2024-12-3112944590core:UnlistedNon-exchangeTraded2024-12-3112944590core:ShareCapital2024-12-3112944590core:SharePremium2024-12-3112944590core:RevaluationReserve2024-12-3112944590core:OtherReservesSubtotal2024-12-3112944590core:RetainedEarningsAccumulatedLosses2024-12-3112944590core:NetGoodwill2023-12-3112944590core:IntangibleAssetsOtherThanGoodwill2023-12-3112944590core:LandBuildings2023-12-3112944590core:PlantMachinery2023-12-3112944590core:Vehicles2023-12-3112944590core:FurnitureFittings2023-12-3112944590core:OfficeEquipment2023-12-3112944590core:AfterOneYear2023-12-3112944590core:WithinOneYear2023-12-3112944590core:ListedExchangeTraded2023-12-3112944590core:UnlistedNon-exchangeTraded2023-12-3112944590core:ShareCapital2023-12-3112944590core:SharePremium2023-12-3112944590core:RevaluationReserve2023-12-3112944590core:OtherReservesSubtotal2023-12-3112944590core:RetainedEarningsAccumulatedLosses2023-12-3112944590core:NetGoodwill2023-01-0112944590core:IntangibleAssetsOtherThanGoodwill2023-01-0112944590core:LandBuildings2023-01-0112944590core:PlantMachinery2023-01-0112944590core:Vehicles2023-01-0112944590core:FurnitureFittings2023-01-0112944590core:OfficeEquipment2023-01-0112944590core:AfterOneYear2023-01-0112944590core:WithinOneYear2023-01-0112944590core:ListedExchangeTraded2023-01-0112944590core:UnlistedNon-exchangeTraded2023-01-0112944590core:ShareCapital2023-01-0112944590core:SharePremium2023-01-0112944590core:RevaluationReserve2023-01-0112944590core:OtherReservesSubtotal2023-01-0112944590core:RetainedEarningsAccumulatedLosses2023-01-0112944590core:AfterOneYear2024-01-012024-12-3112944590core:WithinOneYear2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:CostValuation2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3112944590core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3112944590core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3112944590core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3112944590core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3112944590core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3112944590core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3112944590core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3112944590core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3112944590core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3112944590core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3112944590core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3112944590core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3112944590core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3112944590core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3112944590core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3112944590core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3112944590core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3112944590core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3112944590bus:Director12024-01-012024-12-3112944590bus:Director22024-01-012024-12-31

WLNESS SCIENCE LTD

Registered Number
12944590
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2024

WLNESS SCIENCE LTD
Company Information
for the year from 1 January 2024 to 31 December 2024

Directors

L Lofqvist
J Tagesson

Registered Address

5th Floor 167-169 Great Portland Street
London
W1W 5PF

Registered Number

12944590 (England and Wales)
WLNESS SCIENCE LTD
Balance Sheet as at
31 December 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets5530,799382,188
Tangible assets61,2602,250
532,059384,438
Current assets
Debtors146,66745,333
Cash at bank and on hand359,476384,819
506,143430,152
Creditors amounts falling due within one year(266,516)(89,908)
Net current assets (liabilities)239,627340,244
Total assets less current liabilities771,686724,682
Creditors amounts falling due after one year(1,822,740)-
Accruals and deferred income(2,288)(15,867)
Net assets(1,053,342)708,815
Capital and reserves
Called up share capital149149
Share premium1,485,5092,308,247
Profit and loss account(2,539,000)(1,599,581)
Shareholders' funds(1,053,342)708,815
The financial statements were approved and authorised for issue by the Board of Directors on 23 May 2025, and are signed on its behalf by:
L Lofqvist
Director
Registered Company No. 12944590
WLNESS SCIENCE LTD
Notes to the Financial Statements
for the year ended 31 December 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Defined contribution pension plan
The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.
Share-based payments
The company provides share-based payment arrangements to certain employees. Equity-settled arrangements are measured at fair value (excluding the effect of non-market based vesting conditions) at the date of the grant. The fair value is expensed on a straightline basis over the vesting period. The amount recognised as an expense is adjusted to reflect the actual number of shares or options that will vest. Where equity-settled arrangements are modified, and are of benefit to the employee, the incremental fair value is recognised over the period from the date of modification to date of vesting. Where a modification is not beneficial to the employee there is no change to the charge for share-based payment. Settlements and cancellations are treated as an acceleration of vesting and the unvested amount is recognised immediately in the income statement.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Amortisation
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases: Software 5 years straight line
Research and development
All research costs are expensed. Costs related to the development of products are capitalised when they meet the criteria stated in FRS 102, Section 18 Intangible assets other than Goodwill. All other development expenditure is recognised as an expense in the period in which it is incurred.
Tangible fixed assets and depreciation
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses. Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Straight line (years)
Office Equipment3
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at transaction price and measured at amortised cost using the effective interest method. Where investments in non-derivative financial instruments are publicly traded, or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value through profit and loss. All other investments are subsequently measured at cost less impairment. Financial assets which are measured at cost or amortised cost are reviewed for objective evidence of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. All equity instruments, regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment.
2.Average number of employees

20242023
Average number of employees during the year33
3.Prior period adjustment
During the year, the company identified that revenue and associated direct costs relating to annual app subscriptions for the year ended 31 December 2023 had been recognised in full at the point of sale, rather than being apportioned over the life of the subscription in accordance with the stage of completion method, as required by the company's revenue recognition policy. A prior period adjustment has been made to correct this error. The effect on the previously reported figures for the year ended 31 December 2023 was as follows: Decrease in revenue: £30,524 Decrease in cost of sales: £7,540 Net decrease in net assets: £22,984 Comparative figures have been restated accordingly.
4.Further information regarding the company's income
During the year ended 31 December 2024, the Company revised the presentation of eligible Research and Development (R&D) expenditure within the statement of profit or loss. In the prior year, all eligible R&D costs were presented under a single line item, “Research & Development". Following consultation with the Company's R&D tax advisor, management has determined that allocating such costs to the relevant underlying cost categories aligns the financial statement presentation with the treatment used in the annual R&D tax credit claim submitted to HMRC. Accordingly, eligible R&D costs have been allocated to the following cost lines within operating expenses, based on the nature of the underlying activity: Consulting: £414,975 Consumables: £65,876 IT & Software: £5,443 This change in presentation has no impact on the net assets, profit before tax, or tax position of the Group for the year. The total amount of eligible R&D costs recognised in the year ended 31 December 2024 was £486,294 (2023: £510,275).
5.Intangible assets

Total

£
Cost or valuation
At 01 January 24540,593
Additions255,680
At 31 December 24796,273
Amortisation and impairment
At 01 January 24158,405
Charge for year107,069
At 31 December 24265,474
Net book value
At 31 December 24530,799
At 31 December 23382,188
6.Tangible fixed assets

Total

£
Cost or valuation
At 01 January 243,599
Additions579
At 31 December 244,178
Depreciation and impairment
At 01 January 241,349
Charge for year1,569
At 31 December 242,918
Net book value
At 31 December 241,260
At 31 December 232,250